Under one in 10 patients that would benefit from obesity jabs like Wegovy can access them, caution the World Health Organization as it publishes its initial recommendations on the medications.
Given over a billion individuals worldwide now classified as obese, it is advocating for more widespread and fairer availability to these injectable treatments.
Based on projections, more than two billion are projected to be obese by 2030 without intervention.
"The latest guidelines acknowledges that excess weight is a chronic disease that can be treated with holistic and continuous treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are significant hurdles to widespread access to the injections that can help people shift significant body mass, says the agency.
Skinny Jab Supply Crisis
Despite the current most optimistic case, the manufacturing of such drugs might only reach about 100 million people – fewer than 10% of those who need them, as stated by the WHO.
The advice encourages governments and firms to widen access, through strategies such as voluntary licensing.
A patent on a key compound – the main component of the drug Wegovy – is scheduled to end in multiple countries in 2026.
The Way Weight-Loss Injections Function
These medications replicate a body's own hormone to slow digestion, suppress the appetite and enhance the sense of being full so individuals eat less.
Individuals commonly begin shedding pounds after several weeks of commencing the regular doses.
Studies suggests people may regain a significant portion within a year of discontinuing the treatment, as their typical hunger resume.
To be carrying excess weight increases your chance for developing diseases, including type 2 diabetes, heart disease, stroke, and some cancers.
Excess weight impacts people in all nations and was linked to over three and a half million deaths worldwide in 2024, according to the WHO.
